Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21734251 | 0.91 | MAOA (0.53) | MAOAMAOBHRH3KDM4EGLA | |
| SCHEMBL10963250 | 0.89 | MAOB (0.56) | MAOAMAOBHRH3KDM4EGLA | |
| SCHEMBL9693016 | 0.82 | SLC2A1 (0.57) | MAOAMAOBHRH3KDM4EGLA | |
| SCHEMBL9692361 | 0.82 | SLC2A1 (0.57) | MAOAMAOBHRH3KDM4EGLA | |
| SCHEMBL10967087 | 0.81 | KDM4E (0.74) | MAOAMAOBKDM4EGLARCE1 | |
| SCHEMBL9690674 | 0.80 | LCK (0.53) | MAOAMAOBHRH3CYP2D6HRH1 | |
| SCHEMBL9692105 | 0.80 | LCK (0.53) | MAOAMAOBHRH3CYP2D6HRH1 | |
| SCHEMBL17381541 | 0.80 | KDM4E (0.70) | MAOAKDM4EGLARCE1CYP2D6 | |
| SCHEMBL10455397 | 0.79 | SLC2A1 (0.69) | MAOAMAOBHRH3CYP2D6HRH1 | |
| SCHEMBL9693074 | 0.79 | SLC2A1 (0.69) | MAOAMAOBHRH3CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| EP-3286191-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169911-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016169911-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-10-27 | — | — | WO | disclosed |
| WO-2015197550-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015197550-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | MAOA 2301/4885MAOB 3351/4885HRH3 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.